Literature DB >> 2835552

Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2',5' oligoadenylate synthetase induction.

D Feldman1, A L Goldstein, D C Cox, P M Grimley.   

Abstract

Cultured human umbilical vein endothelial cells and human thoracic aorta endothelial cells were treated with 500, 1,000, and 2,000 IU/ml of recombinant leukocyte alpha-interferon for 2, 4, and 7 days. Tubuloreticular inclusions developed in treated human umbilical vein endothelial cells and human thoracic aorta endothelial cells. The size and number of tubuloreticular inclusions observed correlated with the dose and duration of treatment. Interferon treatment inhibited the rate of proliferation of both human umbilical vein endothelial cells and human thoracic aorta endothelial cells in a dose- and duration-dependent manner. Induction of the interferon-associated enzyme, 2'-5' oligoadenylate synthetase, also occurred. Since the endothelium is exposed to endogenous interferon present in certain pathologic conditions and to exogenous interferon administered in the treatment of several neoplastic or viral diseases, there is an increased need to understand the various effects of interferon on the endothelial cell.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835552

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  14 in total

1.  Inducible release of an endothelial cell-specific protein.

Authors:  C W Carson; G G Hunder; K L Kaplan; C M Johnson
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

2.  Clinical experience with interferon alfa-2a for exudative age-related macular degeneration.

Authors:  J N Kirkpatrick; A D Dick; J V Forrester
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

3.  Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b.

Authors:  M C Gillies; J P Sarks; P E Beaumont; A B Hunyor; D McKay; M Kearns; P J McClusky; S H Sarks
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

Review 4.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 5.  Dermatomyositis and type 1 interferons.

Authors:  Steven A Greenberg
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

Review 6.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

7.  The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.

Authors:  David Fiorentino; Lorinda Chung; Jeff Zwerner; Antony Rosen; Livia Casciola-Rosen
Journal:  J Am Acad Dermatol       Date:  2011-04-29       Impact factor: 11.527

8.  Ultrastructural features and prevalence of tubuloreticular structures in the ocular vasculature of patients with AIDS: a study of 23 cases.

Authors:  R K Maturi; R L Font
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

Review 9.  Targeted immunotherapy trials for idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2012-06-30       Impact factor: 4.849

10.  Accelerated recovery from nephrotic syndrome with acute renal failure by double filtration plasmapheresis in a patient with lupus podocytopathy.

Authors:  Yoshitaka Iwazu; Tetsu Akimoto; Sayoko Izawa; Makoto Inoue; Shigeaki Muto; Yasuhiro Ando; Kana Iwazu; Noriyoshi Fukushima; Wako Yumura; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2012-02-18       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.